The Phase III clinical study NCT0397142, a randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of rozanolixizumab in adult patients with generalized MG, has been completed and enrolled patients with confirmed positive records of AChR or MuSK at screening (200 total MG participants). This evidence concerns the gene MUSK and myasthenia gravis.